Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

18
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
18
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

154
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
154
Inflammation01:38

Inflammation

53.7K
Overview
53.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Biomarkers of post-stroke cognitive impairment-a systematic literature review.

Frontiers in behavioral neuroscience·2026
Same author

Contemporary achievement of guideline recommendations for blood pressure management after stroke in the CONVINCE trial.

European stroke journal·2026
Same author

'It Takes a Village': Sociocultural Insights From a Qualitative Study on Strategies for Member Engagement and Participation in SMART Recovery.

Drug and alcohol review·2026
Same author

Diagnostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in Differentiating Primary From Serious Secondary Headache.

European journal of neurology·2026
Same author

Reconsidering the Term "Patient" in Alcohol and Other Drug Treatment Settings.

Substance use & addiction journal·2026
Same author

Virtual-Only or In-Person Interviews for Residency Applicants.

The New England journal of medicine·2026

相关实验视频

Updated: Jul 14, 2025

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research
07:34

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Published on: December 15, 2023

2.1K

准炎症以减少复发性中风的发生.

Annaelle Zietz1,2, Sarah Gorey3,4,5, Peter J Kelly3,4,6

  • 1Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.

International journal of stroke : official journal of the International Stroke Society
|October 6, 2023
PubMed
概括

炎症在各种类型的中风和复发性血管事件中起着关键作用. 使用生物标志物识别残留炎症风险的患者可以指导未来的抗炎疗法,以预防二次中风.

关键词:
一次性中风,中风.这是一种炎症炎症炎症炎症.炎症生物标志物 炎症生物标志物脑卒中病因 脑卒中病因学预防中风 预防中风

更多相关视频

Isolation and Flow Cytometric Analysis of Immune Cells from the Ischemic Mouse Brain
12:14

Isolation and Flow Cytometric Analysis of Immune Cells from the Ischemic Mouse Brain

Published on: February 12, 2016

35.1K
Modeling Stroke in Mice: Transient Middle Cerebral Artery Occlusion via the External Carotid Artery
07:26

Modeling Stroke in Mice: Transient Middle Cerebral Artery Occlusion via the External Carotid Artery

Published on: May 24, 2021

7.2K

相关实验视频

Last Updated: Jul 14, 2025

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research
07:34

Author Spotlight: Establishing a Reliable Distal MCA Occlusion Model in Mice for Stroke Research

Published on: December 15, 2023

2.1K
Isolation and Flow Cytometric Analysis of Immune Cells from the Ischemic Mouse Brain
12:14

Isolation and Flow Cytometric Analysis of Immune Cells from the Ischemic Mouse Brain

Published on: February 12, 2016

35.1K
Modeling Stroke in Mice: Transient Middle Cerebral Artery Occlusion via the External Carotid Artery
07:26

Modeling Stroke in Mice: Transient Middle Cerebral Artery Occlusion via the External Carotid Artery

Published on: May 24, 2021

7.2K

科学领域:

  • 神经科学是一个神经科学.
  • 免疫学 免疫学 免疫学
  • 心脏病学 心脏病学

背景情况:

  • 回复性血管事件影响大约25%的中风患者,需要改善二次预防.
  • 炎症是冠状动脉样硬化的一个已知的因素,但其在各种中风亚型中的作用尚未完全理解.
  • 根据中风亚型了解炎症的预后价值对于设计有效的抗炎疗法随机对照试验 (RCT) 至关重要.

研究的目的:

  • 审查缺血性中风亚型中的炎症途径.
  • 为了检查炎症标志物和中风后血管复发之间的关联.
  • 评估用于血管预防的抗炎药物的RCT证据.

主要方法:

  • 实验,遗传和成像研究的叙述性回顾.
  • 分析证据,将炎症标志物 (例如IL-6,hsCRP) 与中风复发联系起来.
  • 对研究抗炎疗法用于减轻血管风险的RCT的审查.

主要成果:

  • 炎症与动脉样硬化性中风,小血管疾病 (神经炎症) 和心房动有关.
  • 干白素-6 (IL-6) 和高灵敏性C反应蛋白 (hsCRP) 在识别高风险患者方面表现有前途.
  • 抗炎疗法已证明可以降低冠状动脉疾病的血管风险,目前正在进行预防中风的试验.

结论:

  • 在多种中风病因方面,炎症很重要,这表明抗炎策略的潜在益处.
  • 生物标志物可以识别具有残留炎症风险的患者,用于有针对性的二次中风预防.
  • 建议在未来评估抗炎治疗的RCT中以生物标志物为导向的患者选择.